November 2022 - Corcept Therapeutics

Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search

November 25, 2022

Isaac Sachmechi, MD, FACE, FACP; Sanna Salam; Muhammad Umair, MD; Kathleen Wade Tarnowski, MSc • 2021 •

Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis

November 24, 2022

Albert W. Coo, MD, FACE; Rebecca Ray, FNP-C • 2021 •

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

November 22, 2022

Greenstein et al. • 2020 • AACR Annual Meeting 2020

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.

November 20, 2022

Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)

Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator

November 18, 2022

Lee et al. • 2020 • 2020 Annual Meeting – American Psychiatric Association (APA)

GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

November 17, 2022

Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May

Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients

November 16, 2022

Steffensen et al • 2019 • Horm Metab Res.

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices